“We’ve stepped back into the world that we lived in before the [CDC’s vaccine advisory committee] was created,” said Dr.

Drastic changes are brewing at the FDA, as newly appointed Commissioner Dr. Marty Makary indicates a shift toward stricter scientific accountability in vaccine approvals. In a notable departure from ...

The U.S. Food and Drug Administration may not renew its authorization for Pfizer's COVID-19 vaccine approved for children ...

The move would add another barrier for parents who want to vaccinate healthy children ahead of the respiratory virus season.

The expedited approval of mpox vaccines is critical to addressing this public health emergency. Building on the practice in approving COVID-19 vaccines, this analysis investigates the regulatory ...

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Q2 2025 Earnings Call Transcript August 6, 2025 Novavax, Inc. beats earnings expectations. Reported EPS is $0.601, ...

Discover Novavax's Q2 2025 earnings insights: raised revenue targets, cost reductions, key partnerships with Sanofi & Takeda, and progress in ...

Novavax, sold under the brand name Nuvaxovid, is a protein-based COVID-19 vaccine — the same technology used to develop many other common vaccines, including those for influenza and shingles ...

Novavax’s COVID-19 vaccine is not approved by the FDA yet, but it is available in the U.S. under emergency use authorization, which the FDA issued to the company in July 2022, and allows ...

Novavax uses a protein-based vaccine strategy, which means people getting the vaccine receive a protein made by the virus that their body’s immune systems then see as foreign and mount responses ...

Moderna’s sales soared into the billions as it conquered the coronavirus vaccine market -- and today the company promises to deliver many new products in the near term. Novavax struggled in ...